Responses
Regular and young investigator award abstracts
Clinical trials in progress
406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.
